MarginsXMarginsX
Home › Markets › ELTP

Elite Pharmaceuticals Inc /Nv/ (ELTP)

ELTP is quoted over the counter, not listed on an exchange. Elite Pharmaceuticals Inc /Nv/ files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.

Close · November 16, 2026
$0.3700
+15.6% on the day
1-year return
-45.6%
Market cap
$398.7M
Small cap. From the Nov 16, 2026 close × 1.08B shares (10-Q cover page, Nov 12, 2026)
P/E and P/S
6.6× · 2.8×
On trailing twelve months to September 30, 2026 (10-Q)

Closes: Yahoo Finance daily closes, last bar 2026-11-16.

Profile

FieldValue
TickerELTP, quoted over the counter
SEC CIK0001053369
OTC Markets tierOTCQB (price source, 2026-11-13)
SEC industry codePharmaceutical Preparations
Business addressNorthvale, NJ
Incorporated inNJ

Warning signs

Cash runway
Cash-flow positive
$35.3M cash at September 30, 2026
Share count, 1 year
+0.3%
2025-11-14 to 2026-11-12 · +6.3% over 3 years
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
-$487K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$35.3M cash; operating cash flow $2.7M a quarter.Report 2026-09-30
Shares outstanding1,077,569,775 (2026-11-12); 1,074,496,422 a year earlier; 1,013,915,081 three years earlier.Cover page 2026-11-12
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorForvis Mazars, LLP, Iselin, New Jersey, United StatesPCAOB Form AP 2026-07-30
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $9K, sold $496K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2027
2026-09-30
$40.1M$17.3M-$3.1M$35.3M$94K$144.8M10-Q 2026-11-12
Q1 2027
2026-06-30
$32.4M$5.9M$10.1M$39.4M$94K$141.0M10-Q 2026-08-13
Q4 2026
2026-03-31
$40.7M$18.5M$9.1M$30.3M$93K$148.9M10-K 2026-06-29
Q3 2026
2025-12-31
$31.6M$18.6M-$5.3M$21.6M$92K$140.1M10-Q 2026-02-17
Q2 2026
2025-09-30
$36.3M$13.7M$5.1M$27.1M$100K$122.9M10-Q 2026-11-12
Q1 2026
2025-06-30
$40.2M-$5.9M$14.8M$22.2M$120K$105.5M10-Q 2026-08-13
Q4 2025
2025-03-31
$32.0M$17.0M$3.9M$11.8M$153K$84.0M10-K 2026-06-29
Q3 2025
2024-12-31
$14.4M-$10.9M-$1.1M$8.7M$241K$70.0M10-Q 2026-02-17

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32020-07-27
Latest annual report10-K2026-06-29
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12
Latest proxyDEFA14A2020-05-11

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

The full dossier has every filing, quarterly and annual financials, the health record and a price chart.

Open the full dossier